Since targeting VEGF signaling often normalizes tumor vessels transiently and may ultimately provoke vessel regression, the development of alternative antiangiogenic strategies with a fundamentally distinct mechanism is mandated. The gene discussed is VEGFA; the disease is neoplasm.